25/09/2026 J&J’s guselkumab showed significant improvement in axial PsA FDA approved Lilly's baricitinib for sever AA in paediatric patients aged 12 and older J&J’s guselkumab showed significant improvement in axial PsA (Ref) Johnson & Johnson’s TREMFYA® (guselkumab; anti-IL-23) met its primary and major secondary endpoints in the Phase 4 STAR study in biologic-naïve adults with active psoriatic arthritis and axial involvement (axial PsA). Guselkumab significantly improved sp

31/08/2026 Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases Lilly announced 1-year Ph3b data on ixekizumab and tirzepatide used together in adults with psoriatic disease and obesity Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases (Ref) Eli Lilly and Company and Merida Biosciences announced a definitive agreement for Lilly to acquire Merida Biosciences, a biotechnology

20/07/2026 AbelZeta received EMA PRIME designation for C-CAR168 in LN and SLE LAPIX Therapeutics completed patient enrollment in the RA arm of the ongoing LPX-TI641 clinical trial Almirall announced EMA acceptance of the pediatric filing for Ebglyss® in atopic dermatitis AbelZeta received EMA PRIME designation for C-CAR168 in LN and SLE (Ref) AbelZeta Pharma announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) had granted

09/06/2026 US FDA approved a new every-eight week maintaince dosing option for Lilly’s lebrikizumab in moderate-to-severe atopic dermatitis US FDA accepted Takeda's application for Intravenous vedolizumab in Pediatric UC and CD US FDA approved a new every-eight week maintaince dosing option for Lilly’s lebrikizumab in moderate-to-severe atopic dermatitis (Ref) Eli lilly announced that the US FDA approved a regimen of one maintenance dose every eight weeks of a single injectio

27/02/2026 Lilly's Olumiant recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata Lilly's Olumiant recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata ( Ref ) Eli Lilly and Company and Incyte announced European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion for Olumiant (baricitinib; JAK inhib